AG 4263

Drug Profile

AG 4263

Alternative Names: AG-4263; AnergiX.RA

Latest Information Update: 15 Aug 2007

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Corixa Corporation
  • Developer Corixa Corporation; Organon
  • Class Antirheumatics
  • Mechanism of Action T lymphocyte inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Rheumatoid arthritis

Most Recent Events

  • 17 May 2005 No development reported - Phase-II for Rheumatoid arthritis in USA (IV)
  • 30 Jul 2002 This compound is still in active development
  • 24 Jan 2001 Corixa and Organon have amended their development agreement for AG 4263
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top